Latest Breaking News On - Deniz dalkara - Page 1 : comparemela.com
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
GAMUT
rod-cone dystrophies such as retinitis
pigmentosa
rod-cone dystrophies
today -
Paris,
202
1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed.
SparingVision acquires GAMUT Therapeutics; expanding novel ocular disease pipeline SparingVision will acquire GAMUT Therapeutics, the biotech behind a gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (RP).
GAMUT is a spin-out of the Institut de la Vision in Paris, focused on the research of scientific founder Dr. Deniz Dalkara and her collaborators. It was started in 2020 with seed funding from Advent France Biotechnology.
SparingVision’s SPVN06 already addresses mid-stages of rod-cone dystrophies, while GAMUT’s SPVN20 addresses late stages: giving SparingVision the opportunity to address different stages and potentially combine both products.
SPVN20 joins SPVN06
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non-Human Primates
The
ex vivo retinal stimulation assays also showed that the electrophysiologic response of RGCs expressing ChrimsonR precisely followed the duration and frequency of the light pulses used to activate the opsin. Moreover, localized stimulation of RGCs induced a response coherent with the size and position of the light pulses.
Optogenetic stimulation of RGCs expressing ChrimsonR-tdT can support restoration of visual acuity
The electrophysiological activity of RGCs expressing ChrimsonR-tdT was consistent with the direction and speed of a moving stimulus. Furthermore, the spatiotemporal activation of treated retinas was specific to the shape of the moving symbols presented (square, circle, cross of different sizes), indicating the ability to discriminate between patterns. This level of pattern discrimination corresponded to a Snellen visual acu
vimarsana © 2020. All Rights Reserved.